Valuation : Kamada Ltd.

Market Cap 1.44B 0 474M 408M 384M 350M 655M 45.14B 658M 4.56B 1.76B 23B 1.78B 1.74B 72.85B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 1.44B 0 474M 408M 384M 350M 655M 45.14B 658M 4.56B 1.76B 23B 1.78B 1.74B 72.85B EV / Sales 2026 *
2.37x
EV / Sales 2027 * 2.13x
Free-Float
54.48%
Yield 2026 *
-
Yield 2027 * -
1 day-0.48%
1 week-0.08%
Current month+1.14%
1 month+15.58%
3 months+15.47%
6 months-11.09%
Current year+9.65%
1 week 2,465
Extreme 2465
2,546
1 month 2,013
Extreme 2013
2,578
Current year 2,013
Extreme 2013
2,890
1 year 1,956
Extreme 1956
2,890
3 years 1,685
Extreme 1685
3,045
5 years 1,309
Extreme 1309
3,045
10 years 1,309
Extreme 1309
4,500
Manager TitleAgeSince
Chief Executive Officer 58 2015-06-30
Director of Finance/CFO 56 2017-12-30
Chief Operating Officer 54 2016-10-31
Director TitleAgeSince
Director/Board Member 75 1990-12-12
Chairman 77 2013-03-06
Chairman 55 2020-08-11
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/26 Exercice

VP Quality

6,937 0.0120%
9/2/26 Exercice

Founder

107,166 0.1857%
8/26/26 Exercice

VP Quality

68,328 0.1184%
Change 5-day change 1-year change 3-year change Capi.($)
-0.48%-0.08%+3.38%+20.17% 474M
-0.33%-5.21%+45.12%-2.77% 80.65B
-1.00%-3.42%-19.64%-36.89% 59.12B
-3.36%-10.08%+454.19%+25.98% 54.14B
+0.83%-3.26%-9.28%+30.44% 50.1B
-0.83%-8.07%-2.64%+146.18% 45.33B
-0.83%-5.36%+46.75%-18.63% 31.14B
+1.29%-2.19%+47.21%+96.95% 25.54B
-3.62%-7.85%-5.07%+146.87% 21.8B
-0.02%-3.61%+64.59%+99.91% 16.06B
Average -0.32%-3.60%+62.46%+50.82% 38.44B
Weighted average by Cap. -0.14%-3.85%+78.24%+36.08%

Financials

2026 *2027 *
Net sales 606M 0 200M 172M 162M 148M 276M 19.04B 277M 1.92B 743M 9.7B 751M 735M 30.73B 673M 0 222M 191M 180M 164M 307M 21.16B 308M 2.14B 825M 10.78B 835M 817M 34.15B
Net income 84.8M 0 28.01M 24.1M 22.69M 20.68M 38.68M 2.66B 38.84M 269M 104M 1.36B 105M 103M 4.3B 104M 0 34.39M 29.59M 27.86M 25.39M 47.5M 3.27B 47.69M 330M 128M 1.67B 129M 126M 5.28B
Net Debt - -
Logo Kamada Ltd.
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Employees
462
Date Price Change Volume
26-09-10 ILA 2,478.00 -0.48% 1,154
26-09-09 ILA 2,490.00 +0.08% 130,011
26-09-08 ILA 2,488.00 -0.12% 317,225
26-09-07 ILA 2,491.00 0.00% 57,863
26-09-04 ILA 2,491.00 +0.44% 90,400
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KMDA Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!